UrbanGeekz on MSN
How gene therapy could end sickle cell disease
For generations, Sickle Cell Disease has been a devastating illness affecting millions of people around the world, ...
CRISPR Therapeutics (NasdaqGM:CRSP) is entering a second phase of its business as the CASGEVY commercial rollout gains momentum. The company reports new patient initiations for CASGEVY alongside ...
Are there significant gains ahead for one (or both) of these innovative biotechs?
LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
At the time of the interim analysis, 91.4% (32/35) of patients achieved transfusion independence for 12 consecutive months. The Food and Drug Administration (FDA) has approved Casgevy ™ (exagamglogene ...
Ever since Vertex and CRISPR therapeutics scored a groundbreaking U.K. authorization for their sickle cell gene therapy Casgevy in November, the looming hurdle to commercialization was securing a ...
Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade.
The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results